Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis.

AA, Atrial Arrhythmia ACM, All-cause mortality ACS, Acute coronary syndrome Atrial Arrhythmia CS, Cardiac Sarcoidosis Cardiovascular outcomes HF, Heart failure Heart Failure ICD, Implantable Cardioverter Defibrillator MI, Myocardial infarction Mortality NA, Not available NS, Non-Sarcoidosis OR, Odds ratio Pathology RCT, Randomized Controlled Trial Sarcoidosis VT, Ventricular Tachycardia Ventricular Arrhythmia

Journal

International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 04 05 2022
revised: 14 06 2022
accepted: 19 06 2022
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 9 7 2022
Statut: epublish

Résumé

Sarcoidosis is a chronic inflammatory disorder of unknown etiology associated with high morbidity and mortality. Its association with cardiovascular outcomes is under-documented. The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis. Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA). A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p < 0.001), HF (RR, 4.96; 95% CI: 2.02 to 12.14; p < 0.001) and AA (RR, 2.55; 95% CI: 1.47 to 4.44); p = 0.01) were significantly higher with sarcoidosis respectively compared to non-sarcoidosis. Incidence of VT, HF and AA was significantly higher in patients with CS. Clinicians should be aware of these adverse cardiovascular events associated with sarcoidosis.

Sections du résumé

Background UNASSIGNED
Sarcoidosis is a chronic inflammatory disorder of unknown etiology associated with high morbidity and mortality. Its association with cardiovascular outcomes is under-documented.
Aim UNASSIGNED
The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis.
Methodology UNASSIGNED
Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA).
Result UNASSIGNED
A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p < 0.001), HF (RR, 4.96; 95% CI: 2.02 to 12.14; p < 0.001) and AA (RR, 2.55; 95% CI: 1.47 to 4.44); p = 0.01) were significantly higher with sarcoidosis respectively compared to non-sarcoidosis.
Conclusion UNASSIGNED
Incidence of VT, HF and AA was significantly higher in patients with CS. Clinicians should be aware of these adverse cardiovascular events associated with sarcoidosis.

Identifiants

pubmed: 35800042
doi: 10.1016/j.ijcha.2022.101073
pii: S2352-9067(22)00122-1
pmc: PMC9253999
doi:

Types de publication

Journal Article Retracted Publication

Langues

eng

Pagination

101073

Commentaires et corrections

Type : RetractionIn

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Cardiovasc Electrophysiol. 2014 Aug;25(8):875-881
pubmed: 24602015
Heart. 2011 Dec;97(24):2078-87
pubmed: 22116891
J Am Coll Cardiol. 2020 Aug 18;76(7):767-777
pubmed: 32792073
EClinicalMedicine. 2021 Jun 27;37:100966
pubmed: 34258571
J Dermatol. 2017 Apr;44(4):423-430
pubmed: 27786368
Circulation. 2015 Feb 17;131(7):624-32
pubmed: 25527698
J Am Heart Assoc. 2021 Feb;10(5):e017692
pubmed: 33599141
Ann Transl Med. 2018 Sep;6(17):330
pubmed: 30306069
Am Heart J. 2009 Jan;157(1):9-21
pubmed: 19081391
J Am Coll Cardiol. 2016 Jul 26;68(4):411-21
pubmed: 27443438
Int J Cardiol. 2017 Feb 1;228:68-73
pubmed: 27865201
Nat Rev Cardiol. 2015 May;12(5):278-88
pubmed: 25707386
J Intern Med. 2011 Nov;270(5):461-8
pubmed: 21535250
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28182567
Ann Med Surg (Lond). 2022 Apr;76:103429
pubmed: 35284069
Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):377-85
pubmed: 8372683
Chest. 2013 Apr;143(4):1085-1090
pubmed: 23667912
PLoS One. 2017 May 5;12(5):e0176859
pubmed: 28475583
Med Clin North Am. 2005 Jul;89(4):817-28
pubmed: 15925652
Am J Med Sci. 2018 Feb;355(2):113-125
pubmed: 29406038
Int J Cardiol Heart Vasc. 2022 Apr 11;40:101019
pubmed: 35463916
Am J Cardiol. 2001 Nov 1;88(9):1006-10
pubmed: 11703997
Eur Respir J. 2021 Dec 16;58(6):
pubmed: 34140301
Arrhythm Electrophysiol Rev. 2020 Dec;9(4):182-188
pubmed: 33437485
Adv Exp Med Biol. 2017;980:1-9
pubmed: 28132132
Postgrad Med. 2021 Mar;133(2):202-208
pubmed: 33019840
Am J Med. 1977 Jul;63(1):86-108
pubmed: 327806
Radiographics. 2010 Oct;30(6):1567-86
pubmed: 21071376
J Clin Med. 2021 Oct 29;10(21):
pubmed: 34768590
Syst Rev. 2013 Sep 20;2:76
pubmed: 24050381
Heart. 2022 Mar;108(6):467-473
pubmed: 34021039
Heart. 2006 Feb;92(2):282-8
pubmed: 16415205
Circulation. 2009 Nov 17;120(20):1969-77
pubmed: 19884472
Ann N Y Acad Sci. 1976;278:455-69
pubmed: 1067031
Heart Lung. 2020 Sep - Oct;49(5):512-517
pubmed: 32234258

Auteurs

Vikash Jaiswal (V)

AMA School Of Medicine, Makati, Philippines.

Song Peng Ang (S)

Department of Internal Medicine, Rutgers Health/Community Medical Center, NJ, USA.

Zouina Sarfraz (Z)

Fatima Jinnah Medical University, Lahore, Pakistan.

Swatika Butey (S)

Indira Gandhi Government Medical College, Nagpur, India.

Harshwardhan Vinod Khandait (H)

Department of Internal Medicine, Trinitas Regional Medical Center, Elizabeth, NJ, USA.

David Song (D)

Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Hospital, NY, USA.

Jia Ee Chia (J)

School of Medicine, International Medical University, Kuala Lumpur, Malaysia.

Dipansha Maroo (D)

Maulana Azad Medical College, New Delhi, India.

Muhammad Hanif (M)

Department of Internal Medicine, Suny Upstate Medical University, NY, USA.

Mohammed Ghanim (M)

Henry Ford Healthcare System, Detroit, MI, USA.

Raja Chand (R)

Department of Internal Medicine, Trinitas Regional Medical Center, Elizabeth, NJ, USA.

Monodeep Biswas (M)

General Cardiology and Advanced Heart Failure, Wellspan Cardiology, Lancaster, PA, USA.

Classifications MeSH